Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights
Cybin Inc. Common Shares (CYBN)
Company Research
Source: Business Wire
- Received U.S. Food and Drug Administration (“FDA”) Breakthrough Therapy Designation (“BTD”) for CYB003, its proprietary deuterated psilocybin analog in development for the adjunctive treatment of Major Depressive Disorder (“MDD”) -- Clinical site selection complete for Phase 3 multinational study of CYB003, which is expected to begin in summer 2024 -- Cash totaled C$209 million as of March 31, 2024 -- Initiated a Phase 2 study of CYB004, its proprietary deuterated dimethyltryptamine (“DMT”) program in development for the treatment of Generalized Anxiety Disorder (“GAD”) -- Strengthened intellectual property portfolio with more than 60 granted patents and over 200 pending applications -- Closed oversubscribed private placement of U.S.$150 million (the “Private Placement”) led by a syndicate of leading biopharmaceutical institutional investors - This news release constitutes a “designated news release” for the purposes of Cybin’s prospectus supplements each dated August 23, 2023, to i
Show less
Read more
Impact Snapshot
Event Time:
CYBN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYBN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYBN alerts
High impacting Cybin Inc. Common Shares news events
Weekly update
A roundup of the hottest topics
CYBN
News
- What Makes Cybin Inc. (CYBN) a New Buy Stock [Yahoo! Finance]Yahoo! Finance
- Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]Yahoo! Finance
- Cybin Inc. (NYSE: CYBN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference [Yahoo! Finance]Yahoo! Finance
- Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceBusiness Wire
CYBN
Earnings
- 6/26/24 - Miss
CYBN
Sec Filings
- 6/27/24 - Form 6-K/A
- 6/26/24 - Form 6-K
- 6/26/24 - Form 40-F
- CYBN's page on the SEC website